Drug Recalls

The U.S. Food and Drug Administration (FDA) keeps track of drug recalls and safety alerts. Below is a list of drug recalls that could affect you.

Call Member Services at 1-855-355-9800 or talk to your doctor to find out more.


September 16, 2021 Pfizer expands voluntary nationwide recall to include all lots of Chantix® (varenicline) tablets due to N-nitroso-varenicline content


April 17, 2020 FDA requests removal of all ranitidine products (Zantac) from the market


July 17, 2018 — Prinston Pharmaceutical Inc. Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in the Products

Per the announcement from Prinston Pharmaceutical Inc., as posted by the FDA on its website, “At present Prinston is unaware of any evidence that NDMA has resulted in any harm to patients taking the drugs subject to this recall. To date, Prinston Pharmaceutical Inc. has not received any reports of adverse events related to this recall.

The products are indicated for the treatment of hypertension. 

Consumers and patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on valsartan should continue taking their medication, as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.”

March 2, 2018 — Zinbryta®
Biogen® and AbbVie announced a voluntary withdrawal of Zinbryta (daclizumab), a multiple sclerosis (MS) drug, from the global market, noting concern about the drug’s evolving benefit/risk profile.

Patients using Zinbryta should not stop their medication without talking with their doctor and should contact their doctor immediately for discussion about their options concerning Zinbryta.


August 10, 2017 — Voluntary nationwide recall of all liquid products manufactured by Pharmatech LLC and distributed by Leader® Brand, Major® Pharmaceuticals, and Rugby® Laboratories due to possible product contamination

The products subject to this recall were distributed nationwide to wholesale and retail facilities, including hospitals and pharmacies. As a precautionary measure based on additional information received from the U.S. Food and Drug Administration (FDA), the three distribution firms are recalling all lots within expiry of all liquid products manufactured by PharmaTech LLC.

June 8, 2017 — Opana® ER
After careful consideration and consultation with the FDA following the FDA’s June 2017 withdrawal request, the company has decided to voluntarily remove Opana ER from the market.